OTCMKTS:GNMSF - Genmab Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$193.25 0.00 (0.00 %)
(As of 05/24/2018 04:00 PM ET)
Previous Close$193.25
Today's Range$193.25 - $193.25
52-Week Range$163.00 - $239.75
VolumeN/A
Average Volume254 shs
Market Capitalization$12.53 billion
P/E Ratio71.57
Dividend YieldN/A
Beta0.55

About Genmab (OTCMKTS:GNMSF)

Genmab logoGenmab A/S, a biotechnology company, develops antibody therapeutics for the treatment of cancer primarily in Denmark. The company markets DARZALEX, a human IgG1k monoclonal antibody for the treatment of patients with multiple myeloma (MM); and Arzerra, a human IgG1k monoclonal antibody for the treatment of chronic lymphocytic leukemia (CLL). Its products under development include Ofatumumab to treat CLL, follicular lymphoma, and multiple sclerosis; Daratumumab to treat MM, natural killer/T-cell lymphoma, amyloidosis, and solid tumors; Tisotumab vedotin, HuMax-AXL-ADC, and HexaBody-DR5/DR5 for treating solid cancers; and DuoBody-CD3xCD20 for the treatment of B-cell malignancies. The company's products under development also comprise Teprotumumab for the treatment of Graves' orbitopathy; HuMax-TAC-ADC (ADCT-301) to treat lymphoma and acute myeloid leukemia (AML); HuMax-IL8 (BMS-986253) for metastatic solid tumors; JNJ-61186372 for the treatment of non-small-cell lung cancer; JNJ-63709178 to treat AML; JNJ-64007957 for MM; and AMG 714 for the treatment of celiac disease. In addition, it has approximately 20 active pre-clinical programs, including naked, bispecific, and immune effector function enhanced antibodies. The company has commercial license and collaboration agreement with Seattle Genetics, Inc. to co-develop tisotumab vedotin, an antibody-drug conjugate. Genmab A/S was founded in 1999 and is based in Copenhagen, Denmark.

Receive GNMSF News and Ratings via Email

Sign-up to receive the latest news and ratings for GNMSF and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolOTCMKTS:GNMSF
CUSIPN/A
Phone45-7020-2728

Debt

Debt-to-Equity RatioN/A
Current Ratio18.53
Quick Ratio18.53

Price-To-Earnings

Trailing P/E Ratio71.57
Forward P/E Ratio58.03
P/E GrowthN/A

Sales & Book Value

Annual Sales$359.31 million
Price / Sales32.96
Cash Flow$2.5891 per share
Price / Cash74.64
Book Value$15.57 per share
Price / Book12.41

Profitability

EPS (Most Recent Fiscal Year)$2.70
Net Income$167.62 million
Net Margins45.95%
Return on Equity23.08%
Return on Assets21.40%

Miscellaneous

Employees205
Outstanding Shares61,280,000

Genmab (OTCMKTS:GNMSF) Frequently Asked Questions

What is Genmab's stock symbol?

Genmab trades on the OTCMKTS under the ticker symbol "GNMSF."

How were Genmab's earnings last quarter?

Genmab (OTCMKTS:GNMSF) released its earnings results on Wednesday, November, 5th. The company reported $0.47 EPS for the quarter, beating the Zacks' consensus estimate of $0.45 by $0.02. The company earned $45.65 million during the quarter, compared to analysts' expectations of $53.94 million. Genmab had a return on equity of 23.08% and a net margin of 45.95%. View Genmab's Earnings History.

When is Genmab's next earnings date?

Genmab is scheduled to release their next quarterly earnings announcement on Wednesday, August, 8th 2018. View Earnings Estimates for Genmab.

Who are some of Genmab's key competitors?

Who are Genmab's key executives?

Genmab's management team includes the folowing people:
  • Dr. Jan G. J. van de Winkel, Co-Founder, CEO & Pres (Age 57)
  • Mr. David A. Eatwell, Exec. VP & CFO (Age 57)
  • Dr. Judith Klimovsky, Exec. VP & Chief Devel. Officer (Age 60)
  • Ms. Jane Juel, Sr. Director of Operations & Resource Management
  • Mr. Peter Ros, Sr. Director of Fin. & Accounting and R&D Operations

Has Genmab been receiving favorable news coverage?

Media stories about GNMSF stock have trended positive on Thursday, according to Accern Sentiment Analysis. Accern scores the sentiment of press coverage by monitoring more than 20 million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Genmab earned a media sentiment score of 0.29 on Accern's scale. They also gave news articles about the company an impact score of 47.04 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the stock's share price in the next several days.

How do I buy shares of Genmab?

Shares of GNMSF can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Genmab's stock price today?

One share of GNMSF stock can currently be purchased for approximately $193.25.

How big of a company is Genmab?

Genmab has a market capitalization of $12.53 billion and generates $359.31 million in revenue each year. The company earns $167.62 million in net income (profit) each year or $2.70 on an earnings per share basis. Genmab employs 205 workers across the globe.

How can I contact Genmab?

Genmab's mailing address is BREDGADE 34E, COPENHAGEN G7, . The company can be reached via phone at 45-7020-2728 or via email at [email protected]


MarketBeat Community Rating for Genmab (GNMSF)

Community Ranking:  1.8 out of 5 (star)
Outperform Votes:  70 (Vote Outperform)
Underperform Votes:  126 (Vote Underperform)
Total Votes:  196
MarketBeat's community ratings are surveys of what our community members think about Genmab and other stocks. Vote "Outperform" if you believe GNMSF will outperform the S&P 500 over the long term. Vote "Underperform" if you believe GNMSF will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Genmab (OTCMKTS:GNMSF) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
1 Wall Street analysts have issued ratings and price targets for Genmab in the last 12 months. There are currently 1 hold rating for the stock, resulting in a consensus rating of "Hold."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: HoldHoldHoldHold
Consensus Rating Score: 2.002.002.002.00
Ratings Breakdown: 0 Sell Rating(s)
1 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
2 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
2 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: N/AN/AN/AN/A
Price Target Upside: N/AN/AN/AN/A

Genmab (OTCMKTS:GNMSF) Consensus Price Target History

Price Target History for Genmab (OTCMKTS:GNMSF)

Genmab (OTCMKTS:GNMSF) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetDetails
10/6/2017JPMorgan Chase & Co.DowngradeOverweight ➝ NeutralView Rating Details
4/4/2017Deutsche BankDowngradeBuy ➝ HoldView Rating Details
(Data available from 5/24/2016 forward)

Earnings

Genmab (OTCMKTS:GNMSF) Earnings History and Estimates Chart

Earnings by Quarter for Genmab (OTCMKTS:GNMSF)

Genmab (OTCMKTS:GNMSF) Earnings Estimates

2018 EPS Consensus Estimate: $3.55
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20181$0.72$0.72$0.72
Q2 20181$0.13$0.13$0.13
Q3 20181$0.67$0.67$0.67
Q4 20181$2.03$2.03$2.03

Genmab (OTCMKTS GNMSF) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/8/2018        
11/8/2017Q3 2017($0.01)$51.08 millionViewN/AView Earnings Details
8/9/2017Q2 2017$0.73$114.26 millionViewN/AView Earnings Details
5/10/2017Q1 2017$0.04$35.19 million$35.93 millionViewN/AView Earnings Details
3/28/2017Q4 2016$1.98$134.64 millionViewN/AView Earnings Details
11/2/2016Q3 2016$0.46$54.70 millionViewN/AView Earnings Details
8/9/2016Q2 2016$0.24$0.41$49.68 million$53.72 millionViewN/AView Earnings Details
5/10/2016Q1 2016($0.25)($0.03)$10.31 million$25.15 millionViewN/AView Earnings Details
2/17/2016Q4 2015$0.95$84.32 millionViewN/AView Earnings Details
11/3/2015Q3 2015$0.34$41.41 millionViewN/AView Earnings Details
8/11/2015Q2 2015$0.44$0.04$47.57 million$25.76 millionViewN/AView Earnings Details
5/12/2015Q1 2015$0.55$16.19 millionViewN/AView Earnings Details
11/5/2014Q3 2014$0.45$0.47$53.94 million$45.65 millionViewN/AView Earnings Details
8/13/2014Q2 2014($0.06)($0.08)$26.02 million$20.79 millionViewN/AView Earnings Details
5/7/2014Q1 2014($0.09)$0.33$21.18 million$46.08 millionViewN/AView Earnings Details
11/6/2013Q3 2013($0.01)$0.02$25.52 million$27.12 millionViewN/AView Earnings Details
8/14/2013Q2 2013($0.01)($0.09)$24.45 million$24.54 millionViewN/AView Earnings Details
5/7/2013Q1 2013$0.11$28.09 millionViewN/AView Earnings Details
11/7/2012Q3 2012($0.17)($0.17)ViewN/AView Earnings Details
8/15/2012Q2 2012($0.32)$0.03ViewN/AView Earnings Details
5/15/2012Q1 2012($0.25)($0.23)ViewN/AView Earnings Details
11/2/2011Q3 2011($0.04)ViewN/AView Earnings Details
5/11/2011Q1 2011($0.16)($0.43)ViewN/AView Earnings Details
11/22/2010Q3 2010$0.48ViewN/AView Earnings Details
8/17/2010Q2 2010($0.46)($0.30)ViewN/AView Earnings Details
5/11/2010Q1 2010($0.77)($0.47)ViewN/AView Earnings Details
11/10/2009Q3 2009($1.17)($0.44)ViewN/AView Earnings Details
8/18/2009Q2 2009($1.18)($0.54)ViewN/AView Earnings Details
5/12/2009Q1 2009($1.04)($0.79)ViewN/AView Earnings Details
8/27/2008Q2 2008($1.38)ViewN/AView Earnings Details
5/28/2008Q1 2008($0.95)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Genmab (OTCMKTS:GNMSF) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Genmab (OTCMKTS GNMSF) Insider Trading and Institutional Ownership History

Institutional Ownership Percentage: 0.10%
Insider Trading History for Genmab (OTCMKTS:GNMSF)

Genmab (OTCMKTS GNMSF) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
(Data available from 1/1/2013 forward)

Headlines

Genmab (OTCMKTS GNMSF) News Headlines

Source:
DateHeadline
Genmab (GNMSF) Expected to Post Q3 2018 Earnings of $0.67 Per ShareGenmab (GNMSF) Expected to Post Q3 2018 Earnings of $0.67 Per Share
www.americanbankingnews.com - May 14 at 3:09 AM
Zacks Investment Research Downgrades Genmab As (GNMSF) to SellZacks Investment Research Downgrades Genmab As (GNMSF) to Sell
www.americanbankingnews.com - May 12 at 12:34 AM
Genmab As (GNMSF) Forecasted to Earn FY2018 Earnings of $3.33 Per ShareGenmab As (GNMSF) Forecasted to Earn FY2018 Earnings of $3.33 Per Share
www.americanbankingnews.com - May 11 at 10:47 AM
Genmabs (GNMSF) CEO Jan van de Winkel on Q1 2018 Results - Earnings Call TranscriptGenmab's (GNMSF) CEO Jan van de Winkel on Q1 2018 Results - Earnings Call Transcript
seekingalpha.com - May 9 at 10:05 AM
Genmab As (GNMSF) Raised to "Hold" at Zacks Investment ResearchGenmab As (GNMSF) Raised to "Hold" at Zacks Investment Research
www.americanbankingnews.com - April 25 at 12:47 PM
Analyzing Genmab As (GNMSF) and Celyad (CYAD)Analyzing Genmab As (GNMSF) and Celyad (CYAD)
www.americanbankingnews.com - April 24 at 7:24 PM
Head-To-Head Analysis: Genmab As (GNMSF) & Its PeersHead-To-Head Analysis: Genmab As (GNMSF) & Its Peers
www.americanbankingnews.com - April 24 at 7:48 AM
Zacks Investment Research Upgrades Genmab As (GNMSF) to HoldZacks Investment Research Upgrades Genmab As (GNMSF) to Hold
www.americanbankingnews.com - April 19 at 12:28 AM
Genmab As (GNMSF) Upgraded to "Hold" by ValuEngineGenmab As (GNMSF) Upgraded to "Hold" by ValuEngine
www.americanbankingnews.com - April 5 at 1:11 PM
Analyzing Akebia Therapeutics (AKBA) and Genmab As (GNMSF)Analyzing Akebia Therapeutics (AKBA) and Genmab As (GNMSF)
www.americanbankingnews.com - April 3 at 3:09 AM
Genmab As (GNMSF) Rating Increased to Hold at Zacks Investment ResearchGenmab As (GNMSF) Rating Increased to Hold at Zacks Investment Research
www.americanbankingnews.com - March 31 at 11:09 AM
Genmab (GNMSF) Presents At Deutsche Banks Depositary Receipts Virtual Investor Conference - SlideshowGenmab (GNMSF) Presents At Deutsche Bank's Depositary Receipts Virtual Investor Conference - Slideshow
seekingalpha.com - March 26 at 3:53 PM
Jefferies Group Comments on Genmab As FY2018 Earnings (GNMSF)Jefferies Group Comments on Genmab As' FY2018 Earnings (GNMSF)
www.americanbankingnews.com - February 26 at 6:44 AM
Genmab As (GNMSF) Expected to Earn Q1 2018 Earnings of $0.72 Per ShareGenmab As (GNMSF) Expected to Earn Q1 2018 Earnings of $0.72 Per Share
www.americanbankingnews.com - February 23 at 8:06 AM
Q4 2017 Earnings Forecast for Genmab As Issued By Jefferies Group (GNMSF)Q4 2017 Earnings Forecast for Genmab As Issued By Jefferies Group (GNMSF)
www.americanbankingnews.com - February 7 at 8:18 AM
Genmab Announces 2017 Net Sales Figures for DARZALEX® (Daratumumab)Genmab Announces 2017 Net Sales Figures for DARZALEX® (Daratumumab)
finance.yahoo.com - January 23 at 8:50 AM
U.S. FDA Grants Priority Review for Daratumumab in Front Line Multiple MyelomaU.S. FDA Grants Priority Review for Daratumumab in Front Line Multiple Myeloma
finance.yahoo.com - January 19 at 5:33 PM
Genmab As (GNMSF) Rating Lowered to Sell at Zacks Investment ResearchGenmab As (GNMSF) Rating Lowered to Sell at Zacks Investment Research
www.americanbankingnews.com - January 9 at 11:54 PM
Analysts Issue Forecasts for Genmab As FY2018 Earnings (GNMSF)Analysts Issue Forecasts for Genmab As' FY2018 Earnings (GNMSF)
www.americanbankingnews.com - January 8 at 12:06 PM
ETFs with exposure to Genmab A/S : December 27, 2017ETFs with exposure to Genmab A/S : December 27, 2017
finance.yahoo.com - December 28 at 6:10 AM
Genmab A/S :GNMSF-US: Earnings Analysis: Q3, 2017 By the Numbers : December 26, 2017Genmab A/S :GNMSF-US: Earnings Analysis: Q3, 2017 By the Numbers : December 26, 2017
finance.yahoo.com - December 26 at 9:16 AM
After Soaring 3,000% in 5 Years, Genmab Tests Stock-Market HabitAfter Soaring 3,000% in 5 Years, Genmab Tests Stock-Market Habit
finance.yahoo.com - December 18 at 5:04 PM
Genmab Achieves USD 20 Million Milestone in Daratumumab Collaboration with Janssen and Updates Financial GuidanceGenmab Achieves USD 20 Million Milestone in Daratumumab Collaboration with Janssen and Updates Financial Guidance
finance.yahoo.com - November 29 at 5:24 PM
Genmab A/S (GNMSF) Downgraded by Zacks Investment ResearchGenmab A/S (GNMSF) Downgraded by Zacks Investment Research
www.americanbankingnews.com - November 26 at 3:34 PM
Genmab Announces European Regulatory Submission for Daratumumab in Front Line Multiple MyelomaGenmab Announces European Regulatory Submission for Daratumumab in Front Line Multiple Myeloma
finance.yahoo.com - November 21 at 7:08 PM
Genmab Announces Submission of Supplemental Biologics License Application to FDA for Daratumumab in Front Line Multiple MyelomaGenmab Announces Submission of Supplemental Biologics License Application to FDA for Daratumumab in Front Line Multiple Myeloma
finance.yahoo.com - November 21 at 7:08 PM
Genmab A/S breached its 50 day moving average in a Bullish Manner : GNMSF-US : November 16, 2017Genmab A/S breached its 50 day moving average in a Bullish Manner : GNMSF-US : November 16, 2017
finance.yahoo.com - November 16 at 2:48 PM
Major Shareholder AnnouncementMajor Shareholder Announcement
finance.yahoo.com - November 11 at 7:23 AM
Genmab Announces Financial Results for the First Nine Months of 2017Genmab Announces Financial Results for the First Nine Months of 2017
finance.yahoo.com - November 9 at 6:12 AM
Genmab A/S – Value Analysis (US OTC:GNMSF) : November 1, 2017Genmab A/S – Value Analysis (US OTC:GNMSF) : November 1, 2017
finance.yahoo.com - November 1 at 9:07 PM
Genmab A/S breached its 50 day moving average in a Bullish Manner : GNMSF-US : October 31, 2017Genmab A/S breached its 50 day moving average in a Bullish Manner : GNMSF-US : October 31, 2017
finance.yahoo.com - October 31 at 8:33 PM
Genmab Announces Additional Information Concerning Net Sales of DARZALEX® (daratumumab) for Third Quarter of 2017Genmab Announces Additional Information Concerning Net Sales of DARZALEX® (daratumumab) for Third Quarter of 2017
finance.yahoo.com - October 25 at 2:33 AM
Genmab A/S breached its 50 day moving average in a Bearish Manner : GNMSF-US : October 18, 2017Genmab A/S breached its 50 day moving average in a Bearish Manner : GNMSF-US : October 18, 2017
finance.yahoo.com - October 19 at 12:08 AM
Genmab Announces Net Sales of DARZALEX® (daratumumab) for Third Quarter of 2017Genmab Announces Net Sales of DARZALEX® (daratumumab) for Third Quarter of 2017
finance.yahoo.com - October 17 at 7:52 PM
Seattle Genetics initiates mid-stage of tisotumab vedotin in cervical cancer, positive results may support registrationSeattle Genetics initiates mid-stage of tisotumab vedotin in cervical cancer, positive results may support registration
seekingalpha.com - October 10 at 9:53 PM
Genmab and Seattle Genetics to Initiate New Study of Novel Antibody-Drug Conjugate Tisotumab Vedotin in Cervical CancerGenmab and Seattle Genetics to Initiate New Study of Novel Antibody-Drug Conjugate Tisotumab Vedotin in Cervical Cancer
finance.yahoo.com - October 10 at 4:49 PM
Genmab A/S (GNMSF) Rating Lowered to Neutral at J P Morgan Chase & CoGenmab A/S (GNMSF) Rating Lowered to Neutral at J P Morgan Chase & Co
www.americanbankingnews.com - October 7 at 3:36 PM
Genmab Announces Approval of DARZALEX® (daratumumab) for Relapsed or Refractory Multiple Myeloma in JapanGenmab Announces Approval of DARZALEX® (daratumumab) for Relapsed or Refractory Multiple Myeloma in Japan
finance.yahoo.com - October 2 at 1:56 PM
Genmab A/S breached its 50 day moving average in a Bearish Manner : GNMSF-US : September 18, 2017Genmab A/S breached its 50 day moving average in a Bearish Manner : GNMSF-US : September 18, 2017
finance.yahoo.com - September 18 at 6:43 PM
Genmab A/S :GNMSF-US: Earnings Analysis: Q2, 2017 By the Numbers : September 12, 2017Genmab A/S :GNMSF-US: Earnings Analysis: Q2, 2017 By the Numbers : September 12, 2017
finance.yahoo.com - September 12 at 7:58 PM
Seattle Genetics and Genmab team up to develop ADC tisotumab vedotinSeattle Genetics and Genmab team up to develop ADC tisotumab vedotin
seekingalpha.com - August 30 at 9:33 PM
J&Js Darzalex extends progression-free survival in late-state multiple myeloma study over Velcade/MP aloneJ&J's Darzalex extends progression-free survival in late-state multiple myeloma study over Velcade/MP alone
seekingalpha.com - August 25 at 6:20 AM
Genmab Announces Positive Topline Results in Phase III ALCYONE Study of Daratumumab in Front Line Multiple MyelomaGenmab Announces Positive Topline Results in Phase III ALCYONE Study of Daratumumab in Front Line Multiple Myeloma
finance.yahoo.com - August 25 at 6:20 AM
Genmab A/S – Value Analysis (US OTC:GNMSF) : August 21, 2017Genmab A/S – Value Analysis (US OTC:GNMSF) : August 21, 2017
finance.yahoo.com - August 23 at 7:38 AM
Genmab A/S breached its 50 day moving average in a Bearish Manner : GNMSF-US : August 21, 2017Genmab A/S breached its 50 day moving average in a Bearish Manner : GNMSF-US : August 21, 2017
finance.yahoo.com - August 21 at 6:32 PM
Genmab A/S breached its 50 day moving average in a Bearish Manner : GNMSF-US : August 10, 2017Genmab A/S breached its 50 day moving average in a Bearish Manner : GNMSF-US : August 10, 2017
finance.yahoo.com - August 11 at 12:47 AM
Genmabs (GNMSF) CEO Jan van de Winkel on Q2 2017 Results - Earnings Call TranscriptGenmab's (GNMSF) CEO Jan van de Winkel on Q2 2017 Results - Earnings Call Transcript
seekingalpha.com - August 9 at 7:18 PM
Genmab Announces Financial Results for the First Half of 2017Genmab Announces Financial Results for the First Half of 2017
finance.yahoo.com - August 9 at 7:18 PM
Genmab Announces Net Sales of DARZALEX® (daratumumab) for Second Quarter of 2017Genmab Announces Net Sales of DARZALEX® (daratumumab) for Second Quarter of 2017
finance.yahoo.com - July 18 at 8:51 PM
Genmabs (GNMSF) CEO Jan van de Winkel on Q1 2017 Results - Earnings Call TranscriptGenmab's (GNMSF) CEO Jan van de Winkel on Q1 2017 Results - Earnings Call Transcript
www.msn.com - May 11 at 3:41 AM

SEC Filings

Genmab (OTCMKTS:GNMSF) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Financials are not available for this stock.

Chart

Genmab (OTCMKTS GNMSF) Stock Chart for Thursday, May, 24, 2018

Loading chart…

This page was last updated on 5/24/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.